The JAK2 V617F tyrosine kinase mutation in myelodysplastic syndromes (MDS) developing myelofibrosis indicates the myeloproliferative nature in a subset of MDS patients.
Ohyashiki
K
K
Aota
Y
Y
Akahane
D
D
Gotoh
A
A
Miyazawa
K
K
Kimura
Y
Y
Ohyashiki
J H
JH
D049109:Cell Proliferation; D006801:Humans; D053614:Janus Kinase 2; D020125:Mutation, Missense; D009190:Myelodysplastic Syndromes / Q000235:genetics* / Q000473:pathology*; D055728:Primary Myelofibrosis; D011505:Protein-Tyrosine Kinases / Q000235:genetics*; D011518:Proto-Oncogene Proteins / Q000235:genetics*
D011518:Proto-Oncogene Proteins; D011505:Protein-Tyrosine Kinases; C507924:JAK2 protein, human; D053614:Janus Kinase 2